Veru FY26 Q3 net loss narrows to $7 million; R&D expense rises 44% to $4.4 million

Reuters2026/08/10 10:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Veru posted a fiscal Q3 net loss of USD 7 million, or USD 0.30 per share, narrowing from USD 7.3 million, or USD 0.50.
R&D expense climbed to USD 4.4 million, while G&A expense fell to USD 3.4 million.
Operating loss from continuing operations widened to USD 7.7 million from USD 7.5 million.
Cash, cash equivalents and restricted cash totaled USD 23.9 million at June 30, 2026, up from USD 15.8 million at Sept. 30, 2025.
Phase 2b PLATEAU trial of enobosarm with semaglutide fully enrolled at 239 patients; interim analysis remains on track for calendar Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100630PRIMZONEFULLFEED9806062) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Veru FY26 Q3 net loss narrows to $7 million; R&D expense rises 44% to $4.4 million

You may also like

Crypto prices